We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+39.69%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.16B
AUM Growth
+$655M
Cap. Flow
-$8.33M
Cap. Flow %
-0.26%
Top 10 Hldgs %
29.57%
Holding
149
New
12
Increased
35
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$68M
2
HUM icon
Humana
HUM
+$58.7M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$21M
5
APRE icon
Aprea Therapeutics
APRE
+$19.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$49M
2
ABBV icon
AbbVie
ABBV
+$39.8M
3
SYK icon
Stryker
SYK
+$38.7M
4
MDCO
Medicines Co
MDCO
+$32.8M
5
CI icon
Cigna
CI
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Consumer Staples 0.66%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
51
Zai Lab
ZLAB
$2.62B
$26M 0.82%
625,000
+50,000
+9% +$1.85M
BOLD
52
DELISTED
Audentes Therapeutics, Inc
BOLD
$24.5M 0.78%
410,000
– –
WST icon
53
West Pharmaceutical
WST
$24.9B
$22.9M 0.72%
152,500
– –
MDGL icon
54
Madrigal Pharmaceuticals
MDGL
$11.8B
$22.8M 0.72%
250,200
-22,200
-8% -$2.15M
ALLK
55
DELISTED
Allakos
ALLK
$22.4M 0.71%
235,000
-55,000
-19% -$4.84M
ACHN
56
DELISTED
Achillion Pharmaceuticals
ACHN
$22.2M 0.7%
3,685,000
-140,000
-4% -$810K
INCY icon
57
Incyte
INCY
$24.4B
$21.8M 0.69%
250,000
-62,300
-20% -$5.32M
PTLA
58
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$21.5M 0.68%
900,000
-150,000
-14% -$4.14M
IMMU
59
DELISTED
Immunomedics Inc
IMMU
$21.2M 0.67%
1,000,000
+105,000
+12% +$1.85M
GBT
60
DELISTED
Global Blood Therapeutics, Inc.
GBT
$21.1M 0.67%
265,000
– –
FRPT icon
61
Freshpet
FRPT
$3.22B
$21M 0.66%
355,250
– –
RDUS
62
DELISTED
Radius Health, Inc.
RDUS
$20.2M 0.64%
1,000,200
-299,800
-23% -$7.28M
XENT
63
DELISTED
Intersect ENT, Inc
XENT
$19.9M 0.63%
800,000
-72,500
-8% -$1.47M
NVTA
64
DELISTED
Invitae Corporation
NVTA
$19.4M 0.61%
1,200,000
+75,000
+7% +$1.33M
INSM icon
65
Insmed
INSM
$28.6B
$19.1M 0.6%
800,000
-90,000
-10% -$1.83M
FTSV
66
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$17.7M 0.56%
+450,000
New +$7.23M
TBPH icon
67
Theravance Biopharma
TBPH
$877M
$17M 0.54%
655,200
+105,200
+19% +$2.04M
ADPT icon
68
Adaptive Biotechnologies
ADPT
$3.97B
$16.3M 0.52%
545,000
– –
CI icon
69
Cigna
CI
$74.6B
$15.3M 0.48%
75,000
-141,900
-65% -$26M
HQY icon
70
HealthEquity
HQY
$8.75B
$15.2M 0.48%
+205,000
New +$12.8M
OSW icon
71
OneSpaWorld
OSW
$2.66B
$15.2M 0.48%
+900,000
New +$14.2M
PHR icon
72
Phreesia
PHR
$773M
$15.1M 0.48%
565,000
+204,000
+57% +$5.64M
GH icon
73
Guardant Health
GH
$22.6B
$14.8M 0.47%
190,000
– –
NVCR icon
74
NovoCure
NVCR
$1.91B
$14.5M 0.46%
172,500
– –
CNC icon
75
Centene
CNC
$32.5B
$14.4M 0.46%
229,800
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rock Springs Capital Management held 149 positions worth $3.16B, up 26% from $2.51B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2019 filing shows 12 new, 35 increased, 32 reduced and 19 closed positions. Its largest new stake was Humana: 185,000 shares worth $67.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2019 buy was Humana: 185,000 shares worth $67.8M.
  • Rock Springs Capital Management added most to Johnson & Johnson in Q4 2019, an estimated $68M increase.
  • Rock Springs Capital Management's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $32.8M.
  • Rock Springs Capital Management fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $3.16B portfolio in Q4 2019.
  • Rock Springs Capital Management opened 12 new positions and closed 19 in Q4 2019.
  • Rock Springs Capital Management's portfolio value rose 26% quarter-over-quarter to $3.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.